Assessing the impact of different neutron RBEs on the all solid cancer radiation risks obtained from the Japanese A-bomb survivors data

References

• Beyene J, Moineddin R. 2005. Methods for confidence interval estimation of a ratio parameter with application to location quotients. BMC Med Res Methodol. 5(1):32.
   PubMedGoogle Scholar
• Cordova KA, Cullings HM. 2019. Assessing the relative biological effectiveness of neutrons across organs of varying depth among the atomic bomb survivors. Radiat Res. 192(4):380–387.
   PubMed Web of Science ®Google Scholar
• Cullings HM, Grant EJ, Egbert SD, Watanabe T, Oda T, Nakamura F, Yamashita T, Fuchi H, Funamoto S, Marumo K, et al. 2017. DS02R1: improvements to atomic bomb survivors’ input data and implementation of dosimetry system 2002 (DS02) and resulting changes in estimated doses. Health Phys. 112(1):56–97.
   PubMed Web of Science ®Google Scholar
• Fieller EC. 1940. The biological standardization of Insulin. Suppl J R Statist Soc. 7(1):1–64.
   Google Scholar
• Grant EJ, Brenner A, Sugiyama H, Sakata R, Sadakane A, Utada M, Cahoon EK, Milder CM, Soda M, Cullings HM, et al. 2017. Solid cancer incidence among the life span study of atomic bomb survivors: 1958-2009. Radiat Res. 187(5):513–537.
   PubMed Web of Science ®Google Scholar
• Hafner L, Walsh L, Schneider U. 2021. Cancer incidence risks above and below 1 Gy for radiation protection in space. Life Sci Space Res. 28:41–56.
   Google Scholar
• ICRP. 2003. Recommendations of the international commission on radiological protection (ICRP Publication 92). Ann ICRP 33:71–75.
   Google Scholar
• ICRP. 2007. Recommendations of the international commission on radiological protection (ICRP Publication 103). Ann ICRP 37:51.
   Google Scholar
• Kellerer AM, Rühm W, Walsh L. 2006. Indications of the neutron effect contribution in the solid cancer data of the A-bomb survivors. Health Phys. 90(6):554–564.
   PubMed Web of Science ®Google Scholar
• Kellerer AM, Walsh L. 2001. Risk estimating for fast neutrons with regard to solid cancer. Radiat Res. 156(6):708–717.
   PubMed Web of Science ®Google Scholar
• Little MP. 1997. Estimates of neutron relative biological effectiveness derived from the Japanese atomic bomb survivors. Int J Radiat Biol. 72(6):715–726.
   PubMed Web of Science ®Google Scholar
• Little MP, Muirhead CR. 2004. Derivation of low-dose extrapolation factors from analysis of curvature in the cancer incidence dose response in Japanese A-bomb survivors. IJLR. 1(3):285–299.
   Google Scholar
• Little MP, Pawel D, Misumi M, Hamada N, Cullings HM, Wakeford R, Ozasa K. 2020. Lifetime mortality risk from cancer and circulatory disease predicted from the japanese atomic bomb survivor life span study data taking account of dose measurement error. Radiat Res. 194(3):259–276.
   PubMed Web of Science ®Google Scholar
• Little MP, Wakeford R, Borrego D, French B, Zablotska LB, Adams MJ, Allodji R, de Vathaire F, Lee C, Brenner AV, et al. 2018. Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies. Lancet Haematol. 5(8):346–358.
   PubMed Web of Science ®Google Scholar
• Mean DS86. 1998. Shielded Kerma and organ dose estimates by distance Hiroshima Japan: RERF. [accessed 2021 April 20]. https://www.rerf.or.jp/en/library/data-en/ds86dose/.
   Google Scholar
• Ozasa K, Shimizu Y, Suyama A, Kasagi F, Soda M, Grant EJ, Sakata R, Sugiyama H, Kodama K. 2012. Studies of the mortality of atomic bomb survivors, report 14, 1950–2003: an overview of cancer and noncancer disease. Radiat Res. 177(3):229–243.
   PubMed Web of Science ®Google Scholar
• Preston DL, Lubin JH, Pierce DA. 1993. Epicure user‘s guide. Seattle (WA ): HiroSoft International Corp,
   Google Scholar
• Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. 2007. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 168(1):1–64.
   PubMed Web of Science ®Google Scholar
• Richardson DB, Cardis E, Daniels RD, Gillies M, O'Hagan JA, Hamra GB, Haylock R, Laurier D, Leuraud K, Moissonnier M, et al. 2015. Risk of cancer from occupational exposure to ionising radiation: retrospective cohort study of workers in France, the United Kingdom, and the United States (INWORKS). BMJ. 351:h5359.
   PubMed Web of Science ®Google Scholar
• Roesch WC. 1987. US-Japan joint reassessment of atomic bomb radiation dosimetry in Hiroshima and Nagasaki. DS86. Dosimetry System 1986. Vols. 1 and 2. Hiroshima (Japan): Radiation Effects Research Foundation.
   Google Scholar
• Rühm W, Walsh L. 2007. Current risk estimates based on the A-bomb survivors data – a discussion in terms of the ICRP recommendations on the neutron weighting factor. Radiat Prot Dosimetry. 126(1-4):423–431.
   PubMed Web of Science ®Google Scholar
• Satoh K, Yasuda H, Kawakami H, Tashiro S. 2018. Relative biological effectiveness of neutrons derived from the excess relative risk model with the atomic bomb survivors data managed by Hiroshima University. Radiat Prot Dosimetry. 180(1-4):346–350.
   PubMed Web of Science ®Google Scholar
• Schmid E, Regulla D, Guldbakke S, Schlegel D, Bauchinger M. 2000. The effectiveness of monoenergetic neutrons at 565 keV in producing dicentric chromosomes in human lymphocytes at low doses. Radiat Res. 154(3):307–312.
   PubMed Web of Science ®Google Scholar
• Schmid E, Regulla D, Guldbakke S, Schlegel D, Roos M. 2002. Relative biological effectiveness of 144 keV neutrons in producing dicentric chromosomes in human lymphocytes compared with 60Co gamma rays under head-to-head conditions. Radiat Res. 157(4):453–460.
   PubMed Web of Science ®Google Scholar
• Schneider U, Walsh L. 2009. Cancer risk above 1 Gy and the impact for space radiation protection. Adv Space Res. 44(2):202–209.
   Web of Science ®Google Scholar
• Tran V, Little MP. 2017. Dose and dose rate extrapolation factors for malignant and non-malignant health endpoints after exposure to gamma and neutron radiation. Radiat Environ Biophys. 56(4):299–328.
   PubMed Web of Science ®Google Scholar
• UNSCEAR. 2021, Report from the sixty-seventh UNSCEAR session to the United Nations General Assembly (A/76/46 part 1). New York (NY): United Nations. [accessed 2021 June 7]. https://www.unscear.org/unscear/en/general_assembly_all.html.
   Google Scholar
• Walsh L. 2013. Neutron relative biological effectiveness for solid cancer incidence in the Japanese A-bomb survivors: an analysis considering the degree of independent effects from gamma-ray and neutron absorbed doses with hierarchical partitioning. Radiat Environ Biophys. 52(1):29–36.
   PubMed Web of Science ®Google Scholar
• Walsh L, Hafner L, Straube U, Ulanowski A, Fogtman A, Durante M, Weerts G, Schneider U. 2021. A bespoke health risk assessment methodology for the radiation protection of astronauts. Radiat Environ Biophys. 60(2):213–231.
   PubMed Web of Science ®Google Scholar
• Young RW, Kerr GD. 2005. Reassessment of the atomic bomb radiation dosimetry for Hiroshima and Nagasaki—dosimetry system 2002 (DS02). Vols. 1 and 2. Hiroshima (Japan): Radiation Effects Research Foundation.
   Google Scholar